Glaukos raises full-year sales forecast after Q1 beat

Glaukos

29/04/2026 21:29

Overview

U.S. ophthalmic therapy firm's Q1 net sales rose 41%, beating analyst expectations

Adjusted net loss for Q1 narrowed and beat analyst consensus

Company raised 2026 net sales guidance to $620 mln-$635 mln

Outlook

Glaukos raises 2026 net sales guidance to $620 mln-$635 mln from $600 mln-$620 mln

Company expects 2026 net sales based on latest foreign currency exchange rates

Glaukos cites iDose TR and Epioxa as key growth drivers for 2026

Result Drivers

PRODUCT LAUNCHES - Co cited iDose TR and Epioxa as key drivers of growth in the quarter

GLAUCOMA SEGMENT - Glaucoma net sales rose 47% year-over-year, with U.S. glaucoma sales up 58%

Company press release: ID:nBw7sTx7Ra

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
Beat
$150.60 mln
$136.92 mln (13 Analysts)
Q1 Adjusted Net Income
Beat
-$10.40 mln
-$16.96 mln (11 Analysts)
Q1 Net Income
-$19.80 mln
Q1 Gross Margin
78.00%
Q1 Adjusted Gross Margin
84.00%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Glaukos Corp is $135.00, about 12.8% above its April 28 closing price of $119.63

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)